01 5Duaklir
02 1Tudorza
03 4Tudorza/Eklira
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 190
Growth (%) : New Launch
Aclidinium Bromide/Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 27
Growth (%) : New Launch
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 150
2016 Revenue in Millions : 170
Growth (%) : -12
Aclidinium Bromide/Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 79
2016 Revenue in Millions : 63
Growth (%) : 25
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 110
2017 Revenue in Millions : 150
Growth (%) : -27%
Aclidinium Bromide/Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 95
2017 Revenue in Millions : 79
Growth (%) : 20%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 170
2015 Revenue in Millions : 190
Growth (%) : -11
Aclidinium Bromide/Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 63
2015 Revenue in Millions : 27
Growth (%) : 133
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 77
2018 Revenue in Millions : 95
Growth (%) : -19
Main Therapeutic Indication : Respiratory disorders
Currency : USD
2014 Revenue in Millions :
2013 Revenue in Millions :
Growth (%) :
LOOKING FOR A SUPPLIER?
